Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections
Renee Ackley, Danya Roshdy, Jacqueline Meredith, et al.
Therapeutic Advances in Infectious Disease
|
May 6, 2021
Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned
Danya Roshdy, Maggie McCarter, Jacqueline Meredith, et al.
Thorax
|
July 6, 2022
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial
Zelalem Temesgen, Colleen F Kelley, Frank Cerasoli, et al.
Eclinicalmedicine
|
November 8, 2022
Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis
Michael E DeWitt, Christopher Polk, John Williamson, et al.
Therapeutic Advances in Infectious Disease
|
March 13, 2023
Evaluation of a health system's implementation of a monkeypox care model under the RE-AIM framework
Christopher Polk, Mindy Sampson, Robert T Fairman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 11, 2021
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Zelalem Temesgen, Charles D Burger, Jason Baker, et al.
The Lancet. Respiratory Medicine
|
December 5, 2021
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Zelalem Temesgen, Charles D Burger, Jason Baker, et al.
JAMA
|
August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial
Nicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
The Lancet. Infectious Diseases
|
December 19, 2024
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
Ryan K Shields, Lilian M Abbo, Renee Ackley, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Antimicrobial Agents and Chemotherapy
|
February 26, 2020
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections
Renee Ackley, Danya Roshdy, Jacqueline Meredith, et al.
Therapeutic Advances in Infectious Disease
|
May 6, 2021
Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned
Danya Roshdy, Maggie McCarter, Jacqueline Meredith, et al.
Thorax
|
July 6, 2022
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial
Zelalem Temesgen, Colleen F Kelley, Frank Cerasoli, et al.
Eclinicalmedicine
|
November 8, 2022
Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis
Michael E DeWitt, Christopher Polk, John Williamson, et al.
Therapeutic Advances in Infectious Disease
|
March 13, 2023
Evaluation of a health system's implementation of a monkeypox care model under the RE-AIM framework
Christopher Polk, Mindy Sampson, Robert T Fairman, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 11, 2021
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Zelalem Temesgen, Charles D Burger, Jason Baker, et al.
The Lancet. Respiratory Medicine
|
December 5, 2021
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Zelalem Temesgen, Charles D Burger, Jason Baker, et al.
JAMA
|
August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial
Nicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
The Lancet. Infectious Diseases
|
December 19, 2024
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
Ryan K Shields, Lilian M Abbo, Renee Ackley, et al.
Page
of 2